ClinicalTrials.gg
Active, not recruitingNCT06843590Vibrance-3Updated Sep 25, 2026

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

A Phase 2 interventional study of ALKS 2680 and Placebo in Idiopathic Hypersomnia, sponsored by Alkermes, Inc.. Active, not recruiting at 50 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Alkermes, Inc. · Phase 2, Interventional, and Treatment

Updated Sep 25, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.

Planned enrollment
10th of 27
126 · median 100
Started
2025
with 4 others
Phase 2
10 of 30
3 open now
Primary completion
2026-11
later than 2 of 12 live
Registered
25th of 30
by date
Lead sponsor
2 of 30
Alkermes, Inc.

Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 10th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 25th registered.

Idiopathic Hypersomnia

53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.

Browse Idiopathic Hypersomnia studies →

Open to participants now

12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Idiopathic Hypersomnia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets

03

Conditions studied

  • Idiopathic Hypersomnia

Keywords

  • Idiopathic Hypersomnia
  • IH
  • sleep
  • sleep disorder
  • orexin-2 receptor agonist
  • excessive daytime sleepiness
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is willing and able, in the opinion of the Investigator, to understand and comply with protocol requirements, including: lifestyle considerations and restrictions, adherence to guidance, adherence to actigraphy and diary requirements, if receiving treatment for OSA, adherence to primary OSA therapy over the 30 days prior to Visit 1, and throughout the study, including during overnight visits.
  • Meets the diagnostic criteria of Idiopathic Hypersomnia according to ICSD-3-TR guidelines, confirmed by the diagnostic evaluations (PSG/MSLT/actigraphy) within the previous 10 years

Exclusion criteria

Exclusion Criteria:

  • Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle
  • Has a history or presence at Visit 1 of other (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise subject safety, interfere with any study assessment, or affect the subject's ability to complete the study
  • Is currently enrolled in another clinical study or used any drug or device within 30 days prior to Visit 1
  • Is currently pregnant, breastfeeding, or is planning to become pregnant during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    ALKS 2680, 10 mg- Part A

    Oral tablet containing 10 mg of ALKS 2680 for once daily administration

    Drug: ALKS 2680

  • Experimental
    ALKS 2680, 14 mg -Part A

    Oral tablet containing 14 mg of ALKS 2680 for once daily administration

    Drug: ALKS 2680

  • Experimental
    ALKS 2680, 18 mg- Part A

    Oral tablet containing 18 mg of ALKS 2680 for once daily administration

    Drug: ALKS 2680

  • Placebo comparator
    Placebo- Part A

    Oral placebo tablet for once daily administration

    Drug: Placebo

  • Experimental
    ALKS 2680 Dose 1- Part B

    Oral tablets of ALKS 2680 taken, orally, daily

    Drug: ALKS 2680

  • Placebo comparator
    Placebo - Part B

    Oral tablets of placebo taken, orally, daily

    Drug: Placebo

Interventions

  • Oral tablet containing ALKS 2680 for daily, oral administration

  • DrugPlacebo

    Oral placebo tablet for daily administration

06

What researchers measure

Primary outcomes

  1. Change in Epworth Sleepiness Scale (ESS) from baseline to Week 8 by dose level

    Time frame: Up to 8 weeks

Secondary outcomes

  1. Change in Idiopathic Hypersomnia Severity Scale (IHSS) from baseline to Week 8 by dose level

    Time frame: Up to 8 weeks

  2. Incidence of treatment emergent adverse events

    Time frame: Up to 10 weeks

07

Study locations

50 sites
  • Alkermes Investigator Site
    Cullman, Alabama 35055, United States
  • Alkermes Investigator Site
    Phoenix, Arizona 85054, United States
  • Alkermes Investigator Site
    Little Rock, Arkansas 72211, United States
  • Alkermes Investigator Site
    Los Angeles, California 90025, United States
  • Alkermes Investigator Site
    Redwood City, California 94063, United States
  • Alkermes Investigator Site
    San Francisco, California 94143, United States
  • Alkermes Investigational Site
    Boulder, Colorado 80301, United States
  • Alkermes Investigator Site
    Colorado Springs, Colorado 80918, United States
  • Alkermes Investigator Site
    Brandon, Florida 33511, United States
  • Alkermes Investigator Site
    Miami, Florida 33176, United States
  • Alkermes Investigator Site
    Winter Park, Florida 32789, United States
  • Alkermes Investigator Site
    Atlanta, Georgia 30328, United States
  • Alkermes Investigator Site
    Macon, Georgia 31210, United States
  • Alkermes Investigator Site
    Stockbridge, Georgia 30281, United States
  • Alkermes Investigator Site
    Peoria, Illinois 61637, United States
  • Alkermes Investigator Site
    Kansas City, Kansas 66160, United States
  • Alkermes Investigational Site
    Boston, Massachusetts 02215, United States
  • Alkermes Investigator Site
    Lansing, Michigan 48911, United States
  • Alkermes Investigator Site
    Lincoln, Nebraska 68506, United States
  • Alkermes Investigator Site
    Middletown, New Jersey 07748, United States
  • Alkermes Investigator Site
    Denver, North Carolina 28037, United States
  • Alkermes Investigator Site
    Huntersville, North Carolina 28078, United States
  • Alkermes Investigator Site
    Canton, Ohio 44718, United States
  • Alkermes Investigator Site
    Cincinnati, Ohio 45245, United States
  • Alkermes Investigator Site
    Cleveland, Ohio 44195, United States
  • Alkermes Investigator Site
    Danville, Pennsylvania 17822, United States
  • Alkermes Investigator Site
    Philadelphia, Pennsylvania 19107, United States
  • Alkermes Investigator Site
    Wyomissing, Pennsylvania 19610, United States
  • Alkermes Investigator Site
    Columbia, South Carolina 29201, United States
  • Alkermes Investigator Site
    Austin, Texas 78731, United States
  • Alkermes Investigator Site
    San Antonio, Texas 78229, United States
  • Alkermes Investigator Site
    Sugar Land, Texas 77478, United States
  • Alkermes Investigator Site
    Sugarland, Texas 77478, United States
  • Alkermes Investigator Site
    Madison, Wisconsin 53792, United States
  • Alkermes Investigator Site
    Sydney, New South Wales 2113, Australia
  • Alkermes Investigator Site
    Bedford Park, South Australia 5042, Australia
  • Alkermes Investigator Site
    Clayton, Victoria 3168, Australia
  • Alkermes Investigator Site
    Alken, 3570, Belgium
  • Alkermes Investigator Site
    Namur, 5101, Belgium
  • Alkermes Investigator Site
    Prague, 128 21, Czechia
  • Alkermes Investigator Site
    Bordeaux, Gironde 33000, France
  • Alkermes Investigator Site
    Montpellier, Herault 34295, France
  • Alkermes Investigator Site
    Grenoble, Isere 38043, France
  • Alkermes Investigator Site
    Bologna, 40139, Italy
  • Alkermes Investigator Site
    Milan, 20127, Italy
  • Alkermes Investigator Site
    Verona, 37134, Italy
  • Alkermes Investigator Site
    Zwolle, 8025 BV, Netherlands
  • Alkermes Investigator Site
    Barcelona, 8036, Spain
  • Alkermes Investigator Site
    Madrid, 28036, Spain
  • Alkermes Investigator Site
    Madrid, 28043, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Feb 25, 2025
StartActual
May 22, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06843590
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
May 22, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Sep 25, 2026

Study contacts

Medical Director
study director · Alkermes, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alixorexton

Start the discussion